Stock Events

Stock Events

Matinas Biopharma 

0
78
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q1 2025
Q1 2026
Q2 2026
Next
-0.69
-0.36
-0.02
0.31
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-9.44MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6LJ.MU. It's not an investment recommendation.
Tesla
6
TSLA
NIO
6
NIO
Plug Power
6
PLUG
Altria Group
5
MO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Amarin
AMRN
Mkt Cap295.09M
Amarin Corporation focuses on cardiovascular health products, directly competing with Matinas' omega-3 based therapies.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca operates in similar therapeutic areas, including cardiovascular diseases, potentially competing with Matinas' product pipeline.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline has a broad portfolio that includes treatments for diseases in areas where Matinas Biopharma is also aiming to innovate.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a diverse range of healthcare products that could compete with Matinas Biopharma's developments in infectious diseases and cardiovascular health.
Novartis
NVS
Mkt Cap292.35B
Novartis AG competes in various therapeutic areas including those targeted by Matinas, such as cardiovascular and metabolic conditions.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. has a strong presence in the pharmaceutical industry, with products that could compete with Matinas' pipeline in infectious diseases and beyond.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie operates in several of the same areas as Matinas, including therapies for conditions that require novel delivery mechanisms.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a diverse drug portfolio, including areas of cardiovascular health, competing with Matinas' interests.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, competes across a broad range of therapeutic areas, including those targeted by Matinas.
Sanofi
SNY
Mkt Cap107.39B
Sanofi focuses on healthcare solutions in areas like cardiovascular diseases, which could place it in direct competition with Matinas Biopharma's products.

About

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
Show more...
CEO
Jerome D. Jabbour
Employees
2
Country
United States
ISIN
US5768101058

Listings

STU
DE
6LJ0.STU
MU
DE
6LJ.MU
STU
DE
6LJ.STU
MU
DE
6LJ0.MU

0 Comments

Share your thoughts

FAQ

What is Matinas Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Matinas Biopharma stocks are traded under the ticker 6LJ.MU.
When is the next Matinas Biopharma earnings date?▼
Matinas Biopharma is going to release the next earnings report on November 12, 2026.
What is Matinas Biopharma revenue for the last year?▼
Matinas Biopharma revenue for the last year amounts to 0 EUR.
What is Matinas Biopharma net income for the last year?▼
6LJ.MU net income for the last year is -9.44M EUR.
How many employees does Matinas Biopharma have?▼
As of September 04, 2026, the company has 2 employees.
In which sector is Matinas Biopharma located?▼
Matinas Biopharma operates in the Health & Wellness sector.
When did Matinas Biopharma complete a stock split?▼
The last stock split for Matinas Biopharma was on September 03, 2024 with a ratio of 1:50.
Where is Matinas Biopharma headquartered?▼
Matinas Biopharma is headquartered in BEDMINSTER, United States.